Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment[1]. Sodium benzoate (SB) was well tolerated without evident side effects. Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant schizophrenia[2]. SB significantly impaired memory and motor coordination. Moreover, SB decreased reduced GSH (reduced glutathione) and increased the MDA (malondialdehyde) level in the brain significantly. Short-term consumption of SB can impair memory performance and increased brain oxidative stress in mice[3]. Repeated administration of sodium benzoate (400 and 800 mg/kg i.p.) and sulfasalazine (500 mg/kg orally) for 7 days, i.e. 2 days before and continued for 5 days after acetic acid infusion, significantly attenuated macroscopic damage and disease activity score as compared to disease control[4].
搜索
